Skip directly to content

TB/HIV Project News

The immense worldwide investment of the Global Fund to Fight AIDS, TB and Malaria (GFATM) has proven effective to ensure increased access to an affordable, high-quality, and sustained supply of TB drugs.

Rapid Shift From Global To National Purchase of TB Drugs Increases Risk of Stockouts and Use of Drugs of Unknown Quality
October 26, 2018 — Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.

Activists Urge National TB Programs and Treatment Providers To Discontinue Use of Harmful Injectable Agents in TB Treatment
October 25, 2018 – Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.

Activists Call on Countries and Donors To Immediately Scale Up Use of Life-Saving TB LAM Test
October 25, 2018 – On the first day of the 49th Union World Conference on Lung Health, activists from around the globe kicked off a week of actions by calling on countries, development partners, and donors to end the unacceptable rates of death caused by tuberculosis (TB) in people living with HIV by immediately scaling up the use of TB LAM testing.

National TB Checklist
October 19, 2018 – Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? Our new checklist lays out simply the core elements of an adequate TB response.

Reality Check: The Price of Bedaquiline
October 16, 2018 – Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline, which should be reflected in the price.

Right to Science Submission, October 2018
October 16, 2018 – The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).

TB, Human Rights, and Universal Periodic Review
October 12, 2018 – Universal Periodic Review (UPR) is a process through which the human rights record of each United Nations member state is reviewed by other countries every five years. As a civil society organization, TAG regularly writes and submits these UPR reports analyzing the TB situations in UN member states, and you can review our UPR reports on this page.

An Activists Guide to Bedaquiline
October 5, 2018 – This guide — updated from the original version put out by Treatment Action Group in 2013 — summarizes updated efficacy, safety, and access information about bedaquiline, an essential medication in the treatment of multidrug-resistant TB (MDR-TB).

Funding for TB Research: Recent Momentum Must Inspire Bold Commitments
September 24, 2018 – In advance of the first-ever United Nations High-Level Meeting on Tuberculosis (TB), a new brief from Treatment Action Group (TAG) — Funding for TB Research: Recent Momentum Must Inspire Bold Commitments — shows that global funding for TB research and development (R&D) reached a new high of USD $767.8 million in 2017.

Activists: Call On Your Countries To Use BDQ-Based Regimens to Treat TB
Just download this easy-to-use letter template from GCTA, TAG, and DR-TB STAT.

U.S. TB and Access to Medicines Stakeholder Letter to U.S. Amb. Nikki Haley on HLM Declaration Negotiations
August 8, 2018 – In response to the reopening of negotiations on the TB High-Level Meeting (HLM) political declaration, a coalition of U.S.-based civil society stakeholders have submitted a letter to U.S. Ambassador to the UN, Nikki Haley, urging a diplomatic solution to the contentious provisions on access to medicines.

Additional Translations of TB Activist's Toolkits
July 24, 2018 – Spanish translations of An Activist’s Guide to Tuberculosis Diagnostic Tools and An Activist’s Guide to Tuberculosis Drugs are now available.

Activists Call on Countries and Donors to Immediately Scale Up Use of Life-Saving TB LAM Test
July 22, 2018 – At the TB 2018 pre-conference held on Sunday 22 July 2018, before the International AIDS Conference in Amsterdam, activists from around the globe called on their countries, development partners, and donors, to end the unacceptable death rates caused by TB in people living with HIV by immediately scaling up the use of TB LAM testing.

Strengthening TB Research in NIAID's Tuberculosis Strategic Plan
July 17, 2018 – Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).

Activists Call on Johnson & Johnson to Drop the Price of Bedaquiline
July 12, 2018 – TAG and activist colleagues expressed concern that the high price of bedaquiline — a crucially important drug for treating drug-resistant TB and one that is now being used in South Africa to replace the hearing-loss causing injectable drugs — will limit its uptake. The activists called on Johnson & Johnson, the maker of bedaquiline, to drop the price in all markets to $32 a month or lower (no more than $192 for six months), and  develop further volume-based price reductions at pre-set benchmarks, to both allow for maximal affordability and further incentivize rapid uptake of bedaquiline. 

Videos from a TB Research Briefing for UN Missions, “The Vital Role of Research for TB Elimination
July 5, 2018 – This briefing, held in New York City on June 4, 2018 and hosted by Treatment Action Group, Médecins Sans Frontières, the Stop TB Partnership, the Union, in partnership with the the Permanent Missions of Brazil and India to the United Nations, the World Health Organization and the United Nations Development Programme, to provide information and an opportunity for discussion on the importance of investing in the full spectrum of TB research and adopting principles to guide research to ensure efficiency and equitable access.

TAG Welcomes Price Reductions For TB Medicines
June 19, 2018 – Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required

Tools To Help Support Activists in Engaging National Policy Makers on TB
May 3, 2018 – We just added two great new tools to this page: a brief on TB R&D needs and key asks, and a brief on pediatric TB needs and key asks.

TAGline Spring 2018

New York Community Groups Call on City, State, Federal Actors to Increase Funding for Tuberculosis
March 22 –
Advocates alarmed that budget cuts led to first rise in TB cases in New York City in over 25 years

Is Shorter Better? Understanding the Shorter Regimen for Treating Drug-Resistant Tuberculosis
March 12 – Confused about the shorter regimen for treating Multidrug-resistant TB (MDR-TB)? We were too, so we worked with DR-TB STAT on a brief to understand its pros and cons.

Webinar: It's Time to Deliver - Including Pregnant and Lactating Women in Clinical Research, Pt 1
February 21, 2018 – Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant women as a vulnerable population, among others. Part I of this webinar series was was intended to broaden and build the capacity of civil society and other partners interested in issues related to pregnant and lactating women and research.

Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide
February 5, 2018 – We recently released this innovative new guide for people who have tuberculosis (TB), people who are at risk for it, and the people who take care of them.

Webinar: Good COPs or Bad COPs? Advocacy to Ensure the Prioritization of TB in 2018 PEPFAR Country Operational Plans (COPs)
January 18, 2018 – Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans (COPs) to improve the response to HIV/AIDS. This webinar held on Thursday, January 11 provides key information regarding the PEPFAR COPs process and timelines, TB/HIV services covered by PEPFAR, and what civil society and advocates should prioritize for inclusion in COPs.

Securing a Tuberculosis-Free Future through the Visionary Research of the CDC’s Tuberculosis Trials Consortium
January 10, 2018 – CRAG, the community advisory board to the Tuberculosis Trials Consortium has produced a useful new brief to raise awareness of the TBTC’s accomplishments, show major advancements in TB care resulting from TBTC studies, and make the case for increasing TB research funding at CDC.

TB Activist Toolkits
December 22, 2017 – This 2017 update to the TB/HIV Activist Toolkit modules continues to build and provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and scientific literacy around TB and TB/HIV. The toolkits are now also available in Spanish and Russian.

Webinar: Exploring the Implications of the Delamanid Phase III and STREAM Trial Results
December 14, 2017
– The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a Webinar held on December 12, 2017.

2017 Symposium: Reframing Risk and Accountability for Action to ZERO TB
December 14, 2017
– On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

Changing World Health Organization Global TB Program Leadership
December 1, 2017
– TAG's Executive Director, Mark Harrington, congratulates Dr. Mario Raviglione on his retirement and thanks him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program.

Remarks by Erica Lessem on TB research at the WHO Global Ministerial Conference on Ending TB
November 27, 2017
– In remarks delivered at the first-ever WHO Global Ministerial Conference on Ending Tuberculosis (TB), TAG's Deputy Executive Director of the TB Project, Erica Lessem, describes the urgent need for civil society to drive political action on funding TB R&D, by drawing from lessons and successes of the HIV movement.

The Ascent Begins: Tuberculosis Research Funding Trends, 2005–2016
November 8, 2017 – Global funding for TB research reached a previously unreported high of $726 million in 2016, according to TAG's latest Tuberculosis Research Funding Trends report. This represents a $100 million increase over 2015 levels and marks the first time annual funding for TB research and development (R&D) has exceeded $700 million since TAG began tracking spending in 2005. Although higher than in previous years, this amount remains woefully inadequate when judged against the innovation gaps holding back the response to TB, which is the world’s leading cause of death from a single infectious agent.

Tools to help support activists in engaging national policy makers on TB
October 25, 2017 - Two unprecedented political opportunities are rapidly approaching– the Global Ministerial Conference and the UN High Level Meeting on TB. Civil society and community groups have a critical role to play in raising the profile and understanding of the issues we face in TB among government officials and ensuring that the commitments they make at high-level meetings are translated into urgent investments and actions. To facilitate engagement between civil society and community groups and national policy makers, TAG has created tools and resources to help support grassroots efforts.
September 2017 - The Activist's Guide to the TB LAM Test is written to help support advocacy and activism efforts aimed at  encouraging the uptake of the LAM test across regulatory agencies, donor-funded programs, and National AIDS and TB Progams. This guide discusses LAM as a critically important, true point-of-care diagnostic designed to detect TB in people living with HIV (PLHIV) with low CD4 counts. While providing strategies and messaging to ensure access to this vital diagnostic for people living with both HIV and TB. 

2017 Pipeline Report
July 18, 2017 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

TB Research Action Network 
June, 19 2017 – Treatment Action Group (TAG) has created this list to communicate with scientists interested in opportunities to support TB research. By entering your information, you agree to receive occasional action alerts about steps scientists can take to advocate for TB research (e.g., through sign-on letters, calls to elected representatives, etc.) organized by TAG and its partners. TAG will never share your information with outside parties or post details of the list publicly. When entering your email address, please use the address at which you feel comfortable receiving messages about advocacy opportunities.

Engaging Your Policy Makers Ahead of the TB Ministerial Conference 
June 2017 – In November, Ministers of Health and Finance from 56 of the most high burden TB countries will gather in Moscow for the first ever Ministerial Conference on TB. This webinar provided participants with specific skills on how to engage policymakers ahead of this conference and identify opportunities for civil society engagement. 

Advocating for TB Research Funding for BRICS and Beyond
May 2017 – Inadequate funding for research has contributed to programs' inability to adequately address tuberculosis (TB), the leading infectious killer in the world. The first-ever Ministerial Conference on ending TB will be held in Moscow in November 2017, and will feature 8 thematic areas-- one of which is Scientific Research and Innovation. This webinar discussed necessary steps to make in advance of the Ministerial Conference to ensure strong, concrete commitments for TB research funding come out of it.

An Activist's Protocol Review Toolkit
May 2017 – An Activist's Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols. The three tools contained in the toolkit will help Community Advisory Boards (CABs) think through different aspects of trial design and implementation, organize feedback for the research team, and evaluate impact on study design and implementation.


Mark Harrington's keynote speech at the Critical Path to TB Drug Regimens
March 20, 2017 – Mark Harrington, TAG's executive director, included in his keynote speech at the Critical Path to TB Drug Regimens meeting the importance of public and private sector funding for research, of thoughtful regulatory strategies, and of rapid uptake of new, evidence-based tools. 

President’s Budget Blueprint Threatens Research Essential to End the Epidemics of HIV/AIDS, TB, and HCV
March 20, 2017 – TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.

Sign-on Letter to Protect the NIH Fogarty International Center
March 20, 2017 – Sign-on letter urging Congress to reject the elimination of the Fogarty International Center at the NIH in the President’s FY 18 budget proposal and to oppose any funding cuts associated with supporting scientific research.

An Activist’s Guide to Tuberculosis Diagnostic Tools
February 2017 - Understanding tuberculosis (TB) diagnosis is critical to understanding why the world is currently failing to end TB. Nearly half of people with TB—over 4 million per year—are undiagnosed, leaving them ill and at risk of death and with the potential to transmit disease to others.  Closing this massive gap will require much better use of the current diagnostic methods, as well as research into faster, simpler, more accurate, and less expensive options.

An Activist’s Guide to Tuberculosis Diagnostic Tools provides an overview of the different tests and strategies for detecting TB, including their benefits and limitations. The guide also makes recommendations for how activists and clinicians can contribute to improved TB diagnosis.

Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
January 24, 2017 –
While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability

Increasing Funding for TB Research: An Advocacy Strategy Webinar
On November 16, 2016, TAG held a community webinar on advocacy for TB R&D funding. This webinar builds upon TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017. Panelists discussed the importance of TB research and implications of stagnant funding, shared insights into what to expect in the TB R&D pipeline, and strategized on what we can do as a community to push for change and the necessary political will under a new US presidential administration.

2016 Symposium Stop Double Standards: From Prevention through Cure to ZERO TB (VIDEO)
On October 27, 2016, in Liverpool, UK, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
OCTOBER 25, 2016 – Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose. In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.

Funding for Tuberculosis Research Falls to Lowest Level in Seven Years
LIVERPOOL, UNITED KINGDOM, OCTOBER 25, 2016—Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to a report issued today by Treatment Action Group (TAG). In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.

Petition to BRICS countries to triple funding for TB R&D
OCTOBER 17, 2016 – Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).

Breakthrough: Catalyzing R&D to End TB
October 2016 – There is great hope for ending tuberculosis (TB)—the world’s leading infectious disease—thanks to both scientific progress and increased ambition from policymakers. But achieving this goal will require more investments in research and development (R&D). With funding trends distressingly on the decline for TB R&D, political action is critical to bend the curve up toward the development of breakthrough diagnostics, treatments, and vaccines needed to realize the promise of ending TB.

AN ACTIVIST’S GUIDE TO Tuberculosis Drugs 2016 Update
October 2016 – Tuberculosis (TB) has been curable for decades, but a rise in the number of people living with drugresistant TB (DR-TB) and TB/HIV coinfection challenges global targets of zero TB deaths, new infections, suffering, and stigma. Although TB and the people it affects have changed over the years, for the most part the drugs used against it have not. In 2012, bedaquiline, used to treat DR-TB, became the first new TB drug from a new class to be approved by the U.S. Food and Drug Administration (FDA) in over 40 years; its accelerated approval was followed in 2014 by the European Medicines Agency’s (EMA’s) conditional approval of bedaquiline and another new drug, delamanid, for the treatment of some forms of DR-TB.

TAGline Fall 2016

TAG Responds to the Release of the World Health Organization's 2016 Global Tuberculosis Report
October 13, 2016 – TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated.

2016 Pipeline Report
July 15, 2016 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations
June 2016 – This policy brief provides an overview of investments made by the U.S. government and explains how increasing TB R&D funding can catalyze the development of better vaccines, diagnostics, and treatments for TB. It is built upon resource tracking and reporting done by Treatment Action Group (TAG), and it recommends areas in which investments will not only fill research gaps but also provide clarity in the vision proposed by the National Action Plan and prevent the rising threat of multidrug-resistant TB (MDR-TB).

TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility
February 24, 2016 – Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed. TAG commends the GDF and the Stop TB Partnership for their leadership in securing access to delamanid with minimal barriers and at a single flat price for all Global Fund-eligible countries.

TAG’s Response to the U.S. Action Plan for Combating Multidrug Resistant Tuberculosis
January 7, 2016 – Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.

An Activist’s Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment
December 2015 – This guide explains different regulatory processes and terms and offers examples of how to use a variety of regulatory mechanisms to improve access to treatment. The guide also encourages activists to advocate for effective, efficient, transparent regulatory systems.

Tuberculosis Research Funding Crisis Imperils Elimination Goal
November 30, 2015, Cape Town, South Africa – Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.

Symposium: Scale Up to Get Down to Zero TB Deaths, New Infections, and Suffering
In conjunction with the 2015 Union World Conference on Lung Health Conference
Friday, December 4, 2015
18h00 – 20h30
Southern Sun The Cullinan, Protea 1 & 2
1 Cullinan Street Cape Town Waterfront
Cape Town, South Africa 8001

TAG Response to the Release of the World Health Organization’s 2015 Global Tuberculosis Report
October 28, 2015: Global leaders’ half-hearted response has enabled TB to overtake AIDS as the world’s leading cause of death from an infectious disease.

September 15, 2015: TAG signed on to an open letter to India’s Minister of Health and Family Welfare calling for the immediate scale-up of GeneXpert machines and MTB/RIF cartridges, which are capable of detecting TB disease and rifampicin resistance in just two hours. The letter highlights critical delays in procurement of these machines and cartridges, underutilization of available machines, cartridge stock-outs, and lack of access to this technology for people living with HIV.

September 3, 2015: On behalf of TAG, the TB CAB, and other allied organizations and individuals, Universities Allied for Essential Medicines (UAEM) presented the president of the Johns Hopkins University with a petition calling for transparency and assurances of non-exclusivity as the university negotiates a licensing agreement for the promising TB drug sutezolid.

August 12, 2015: TAG signed on to an open letter calling for Indian health and municipal authorities to urgently address increasing rates of occupationally acquired TB at Sewri Hospital in Mumbai—Asia’s largest TB hospital. Inadequate infection control measures and access to personal protective equipment have left health care workers at Sewri Hospital without means to protect their health and safety. The letter outlines several measures that health and local authorities can take to better protect health care workers from TB.

August 10, 2015: TAG signed on to an open letter calling for the prioritization of human rights in The Global Plan to Stop TB, 2016–2020. The signatories outline international instruments that establish legal rights for people with TB and encourage members of the Global Plan Development Task Force to more fully integrate a clearly developed human rights–based approach into the Global Plan.

2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

2014 Report on Tuberculosis Research Funding Trends, 2005–2013. 2nd Edition
October 22, 2014 – Reader beware: funding data presented in this report may be less encouraging than they appear. A quick glance at Treatment Action Group’s ninth annual Report on Tuberculosis Research Funding Trends would suggest good news: funding for tuberculosis research and development (TB R&D) increased by US$37.9 million over 2012 to reach a total of $676.7 million in 2013. The foundation of the TB research enterprise, however, is shakier than at any other time since Treatment Action Group (TAG) began tracking funding levels in 2005.

2014 Symposium: Zero Accountability: When Action Doesn’t Match the Numbers (Video)
On October 30, 2014, in conjunction with the Union World Conference in Barcelona, Spain, Treatment Action Group (TAG), the Stop TB Partnership, Médecins Sans Frontières (MSF), Partners In Health (PIH), and the Harvard Medical School Department of Global Health and Social Medicine sponsored a symposium titled “Zero Accountability: when action doesn’t match the numbers.” The symposium began with an introduction highlighting inadequacies in the global response to the MDR-TB emergency. Two panels, with individual talks followed by panel-wide discussions, then convened around the current state of research and development for MDR-TB, including the complexity and duration of existing treatments, and key access issues, including pricing and the uptake of new drugs and regimens.

Letter to the South African Medicines Control Council
October 20, 2014 – TAG signed on to an open letter to the Medicines Control Council, urging them to register a generic version of linezolid to make it available for all patients with drug-resistant TB in need throughout South Africa. Brand-name linezolid is exorbitantly expensive, and out of the reach of most people who need this potentially lifesaving antibiotic. Without access to this quality-assured generic version of linezolid, many patients with difficult-to-treat forms of TB are denied treatment. See press coverage on the letter.

Activists Urge Otsuka to Provide Access to TB Drug – Only a handful of patients have received Otsuka’s new drug, delamanid –
October 30, 2014, Barcelona, Spain – Tuberculosis (TB) activists interrupted Otsuka’s symposium at the 45th Conference on World Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB (MDR-TB).

Otsuka Action At Union 2014


TB Activists demand accountability for lack of compassionate use of new TB drug delamanid, made by Otsuka, at the Union Conference in Barcelona, 2014.

Two New Activist Guides on Delamanid and Linezolid
September 23, 2014 – Delamanid (also called Deltyba), the newest drug to fight tuberculosis (TB) was approved in Europe and Japan in 2014. An Activist’s Guide to Delamanid explains what we know about the drug’s efficacy and safety. Linezolid, an older drug important for treating some cases of drug-resistant TB, is being used more and more, and An Activist’s Guide to Linezolid summarizes the information we have on linezolid’s safety and efficacy in TB treatment. Both guides describe what activists—including people with TB, researchers, and doctors who treat TB—can do to help ensure access, fair pricing, and further research.

SAVE THE DATE: Zero Accountability: When Action Doesn't Match the Numbers: Thursday, October 30, 2014, Barcelona
Please join us for a symposium at the 2014 International Union Against TB and Lung Disease World Conference. Keynote speaker Mark Dybul, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria, will talk about financing the emergency response.

September 10, 2014: TAG and a coalition of organizations and individuals working on TB sent an open letter to Janssen appealing to the company to lower bedaquiline's price for all non-high-income countries. They also requested a September 2014 meeting with the company, policy makers, and key funders of TB drug procurement to make bedaquiline accessible affordably.

2014 Pipeline Report
July 20, 2014 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Read the TB chapters online:

An Activist's Guide to Tuberculosis Drugs
May 29, 2014 – TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities. This guide provides a brief summary of safety and efficacy data for those drugs currently in use for TB (many of which have been approved for other diseases but are used off-label for TB), and suggests advocacy points for activists.

TB in TAGline Spring 2014:

Falling Funding for Tuberculosis Research Threatens to Derail TB Elimination Efforts in the United States
Research Dollars Drop Just as Old Disease Grows More Difficult to Treat

March 24, 2014, Washington, D.C. – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat, a new policy brief released today by Treatment Action Group (TAG) shows. Analysis conducted by TAG reveals that spending on TB research and development (R&D) among U.S. government agencies declined from 2009 to 2012 in the face of budget instability, sequestration, and the rising costs of biomedical research.

Flatlined: U.S. Government Investments in Tuberculosis Research and Development, 2009–2012
March 2014 – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat. In 1989, the U.S. government committed to ending the TB epidemic through the formation of a national TB elimination plan. Since then, the heart of the U.S. strategy for domestic TB elimination has progressed through a combination of visionary research linked to bold implementation. As a result of this two-pronged strategy, there were only 9,951 new domestic cases of TB in 2012, the lowest level since reporting began in 1953. Yet falling funding for TB research threatens to roll back the hard-won achievements of the last two decades.

CRAG, TAG Welcome Sanofi U.S. Commitment to Reduce the Price of Tuberculosis Drug Rifapentine
December 12, 2013 – The Community Research Advisors Group (CRAG) and Treatment Action Group (TAG) welcome the Sanofi U.S. decision to lower the price of the tuberculosis (TB) drug rifapentine to $32 per 32-tablet blister pack. The company indicates that the new price will become effective in January 2014 under 340(b) Public Health Service pricing.

Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing
November 22, 2013 – Approval of and access to delamanid are crucial while further research is pending
New York, New York – Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.

Zeros Action at Stop TB Symposium


Vimeo is the home for high-quality videos and the people who love them.

October 30, 2013 – Activists stormed the stage at the World Health Organization (WHO) sponsored Stop TB Symposium during the 44th Union World Conference on Lung Health. TAG's TB Project Director Colleen Daniels called for global action and a new global attitude in the fight against TB.

Tuberculosis: Behind the Numbers Video Series

November 1, 2013 – Treatment Action Group launches three-video series, produced by filmmaker Jonathan Smith and titledTuberculosis: Behind the Numbers, on PLOS Medicine’s Community Blog, Speaking of Medicine.

  • Mike Frick and Audrey Zhang discuss the need to modernize directly observed therapy and move toward patient-centered care for both drug-sensitive and drug-resistant TB patients, highlighted in the video, A Walk to Work with Dr. Vivian Cox.

Behind the Numbers: A Walk to Work with Dr. Vivian Cox


Vimeo is the home for high-quality videos and the people who love them.

  • Lindsay McKenna and Colleen Daniels describe the importance of access to timely diagnosis and appropriate treatment for patients with drug-resistant TB, and demand that urgency be returned to the global response, underscored in the video,Drs. Dalene and Arne von Delft.

MDR-TB Behind the Numbers: Drs. Dalene and Arne von Delft


Vimeo is the home for high-quality videos and the people who love them.

  • The third and final video, Breaking the Record with Dr. Bart Williams, illustrates the story of a South African doctor and his experience completing treatment for drug-sensitive TB.

Behind the Numbers: Breaking the Record with Dr. Bart Willems


Vimeo is the home for high-quality videos and the people who love them.

A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts
As Threat of Drug-Resistance Grows, Big Pharma Decreases Investments in TB research by 22 Percent
October 29, 2013, Paris, France – The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.

TB in TAGline Fall 2013:

Webcast: New Approaches to Drug-Resistant Tuberculosis
October 2013 – Mark Harrington, executive director of TAG, was featured in an online panel discussion about the global crisis of drug-resistant tuberculosis (DR-TB). The webcast was hosted by Doctors Without Borders/Médecins Sans Frontières (MSF) and New York Times science writer Denise Grady. The panel comprised health care workers and patient advocates working to improve treatment for people living with DR-TB, including Dr. Grania Brigden, TB advisor, MSF Access Campaign; Cathy Hewison, TB medical advisor at MSF; Mark Harrington, executive director of Treatment Action Group; and Evaline Kibuchi, senior TB advocacy manager at the Kenya AIDS NGO Consortium (KANCO).

First-Ever Targeted Roadmap Outlines Steps to End Childhood TB Deaths
Cost to end deaths from childhood TB estimated to be at least US$120 million annually
October 1, 2013, Washington, D.C. – The deaths of more than 74 000 children from tuberculosis (TB) could be prevented each year through measures outlined in the first ever action plan developed specifically on TB and children.

Treatment Action Group Criticizes European Refusal of New Drug to Fight Tuberculosis
 — Approval of and access to delamanid is crucial while further research is pending —
July 29, 2013 – Treatment Action Group (TAG) is disappointed by the failure of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB).

2013 Pipeline Report Calls on Leaders to Get the Best HIV, Hepatitis C Virus, and Tuberculosis Drugs, Diagnostics, and Vaccines to the Most People as Quickly as Possible
June 30, 2013, Kuala Lumpur, Malaysia – HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

TB in TAGline Spring 2013:

Children with Drug-Resistant Tuberculosis Require Urgent Attention
Research and access required to achieve zero deaths, new infections, and suffering—
March 21, 2013 – Treatment Action Group (TAG), in partnership with the Sentinel Project on Pediatric Drug-Resistant Tuberculosis (Sentinel Project) released today We Can Heal: Prevention, Diagnosis, Treatment, Care and Support: Addressing Drug-Resistant Tuberculosis in Children. This collection, released in anticipation of World TB Day on March 24, calls for urgent attention to the global problem of pediatric drug-resistant tuberculosis (DR-TB). The stories of 30 children with DR-TB in 30 countries are a testament to the need for improved programs, policies, and tools to reach the goal of zero TB deaths, new infections, and suffering.

An Activist’s Guide to Bedaquiline (Sirturo)
March 12, 2013 – New drugs are urgently needed to get to zero deaths, zero new infections, and zero stigma and suffering from tuberculosis (TB). While TB has been curable for decades, existing drugs have to be taken for months or even years. Even then, cure rates can range from 30% to 80% for cases of drug-resistant TB, depending on the extent of resistance. People with drug-resistant TB must resort to second-line drugs, which are more toxic, less effective, and more expensive. However, in December 2012, a new drug called bedaquiline was approved for the treatment of multidrug-resistant TB (MDR-TB). Bedaquiline (also known by its trade name, Sirturo, or as TMC207) is the first new drug from a new drug class to treat TB to be approved by the United States Food and Drug Administration (FDA) in over 40 years. This guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward.

TB in TAGline Winter 2013:

Video from A Silent Crisis
January 18, 2013 – the TAG sponsored federal advocacy meeting on tuberculosis drug shortages in the United States available online.

Treatment Action Group Lauds FDA Approval of First New Tuberculosis Drug in Half a Century
December 31, 2012 – Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.

November 28, 2012TAG’s Executive Director Mark Harrington testifies at the FDA Anti-Infective Drugs Advisory Committee Hearing on the Use of Bedaquiline for Treatment of Multidrug-Resistant Tuberculosis.

November 13, 2012Aspiring to Zero TB Deaths, New Infections, and Suffering Symposium videos from the 43rd Union World Conference on Lung Health available online.

Treatment Action Group and the Stop TB Partnership Issue Update on 2011 Global TB R&D Investment Trends
— 2011 Funding Increases 3% to US$649.6 Million, but Annual US$1.35 Billion Funding Gap Remains —
November 14, 2012 | KUALA LUMPUR, MALAYSIA – For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding. The 2012 Report on Tuberculosis Research Funding Trends: 2005–2011 finds 81 donors invested US$649.6 million in TB R&D, an 82% increase from the baseline year of 2005, but only a 3% increase over 2010 funding levels.

Treatment Action Group and European AIDS Treatment Group Applaud UNITAID Agreement to Reduce the Cost of GeneXpert Rapid TB Test
Call for Further Price Cuts on Cartridges and Machines to Realize Goals of Zero TB deaths—
August 7, 2012 – Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG) welcome the announcement that a deal has been reached among PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB). The partners to this collaborative market intervention have taken an important first step towards accelerating market entry to the molecular diagnostic system, which accurately diagnoses both TB and some common drug-resistance mutations, within two hours.  But the still high cost of the machines and cartridges and the lack of private sector access greatly limit the reach and impact of this historic agreement.

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery
Recent Advances in Biomedical HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Prevention and Treatment Are Not Reaching Those Who Need Them Most 
Political Leaders Continue to Break Domestic, Global Health Commitments—
July 21, 2012 | WASHINGTON, D.C., USA–On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.

Children with Drug-Resistant TB Make Up the Most Neglected Patient Population & Treatment Action Group Finds Global TB R&D Rose by Just 2% from 2009: Less than One-Third of the Global Need
March 22, 2012 – In recognition of World Tuberculosis day on March 24th, Treatment Action Group (TAG) calls for the re-focusing of attention on the tremendous burden that tuberculosis (TB) plays around the world. TB is a disease of the poor – more than 80% of TB cases worldwide arise in the global south. According to the World Health Organization, nearly 4,000 people die every day because of TB.  There were 8.8 million people newly diagnosed with TB in 2010, including 1.1 million cases among people with HIV – which, coupled with the emergence of drug resistant TB, including some untreatable strains – creates a deadly synergy. Despite this reality, investment in TB research has remained very low compared to the worldwide burden.

Treatment Action Group Issues Latest Update on Global TB R&D Investment Trends
2010 Funding Flat at $617 million, Less Than One-Third of the Global Need—
October 26, 2011 – LILLE, France – New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005.